{"organizations": [], "uuid": "19e6c11578ac3c5725736ac88225e79a5f5af7a3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-puma-biotechnology-says-emas-chmp/brief-puma-biotechnology-says-emas-chmp-has-communicated-a-negative-trend-vote-for-its-breast-cancer-treatment-neratinib-idUSFWN1PI18F", "country": "US", "domain_rank": 408, "title": "BRIEF-Puma Biotechnology Says EMA's CHMP Has Communicated A Negative Trend Vote For Its Breast Cancer Treatment, Neratinib", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-23T23:33:00.000+02:00", "replies_count": 0, "uuid": "19e6c11578ac3c5725736ac88225e79a5f5af7a3"}, "author": "", "url": "https://www.reuters.com/article/brief-puma-biotechnology-says-emas-chmp/brief-puma-biotechnology-says-emas-chmp-has-communicated-a-negative-trend-vote-for-its-breast-cancer-treatment-neratinib-idUSFWN1PI18F", "ord_in_thread": 0, "title": "BRIEF-Puma Biotechnology Says EMA's CHMP Has Communicated A Negative Trend Vote For Its Breast Cancer Treatment, Neratinib", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}], "organizations": [{"name": "ema", "sentiment": "negative"}, {"name": "brief-puma biotechnology says ema", "sentiment": "negative"}, {"name": "neratinib reuters staff", "sentiment": "none"}, {"name": "puma biotechnology inc", "sentiment": "none"}, {"name": "neratinib", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "puma", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 23, 2018 / 9:33 PM / Updated 8 minutes ago BRIEF-Puma Biotechnology Says EMA's CHMP Has Communicated A Negative Trend Vote For Its Breast Cancer Treatment, Neratinib Reuters Staff 1 Min Read \nJan 23 (Reuters) - Puma Biotechnology Inc: \n* PUMA BIOTECHNOLOGY ANNOUNCES RESULTS OF CHMP ORAL EXPLANATION FOR NERATINIB FOR EXTENDED ADJUVANT TREATMENT OF HER2-POSITIVE EARLY STAGE BREAST CANCER \n* PUMA BIOTECHNOLOGY - CHMP USE OF EMA COMMUNICATED NEGATIVE TREND VOTE AFTER MEETING WITH CO TO DISCUSS MAA FOR NERATINIBâ€‹ \n* PUMA BIOTECHNOLOGY - NEGATIVE TREND VOTE MEANS IT IS UNLIKELY CHMP WILL PROVIDE POSITIVE OPINION RELATED TO MAA AT FORMAL DECISION VOTE IN FEB. 2018 \n* PUMA BIOTECHNOLOGY - NEGATIVE TREND VOTE ALSO MEANS ADDITIONAL STEPS WOULD NEED TO BE TAKEN TO GAIN MARKETING APPROVAL IN EUROPE \n* PUMA BIOTECHNOLOGY - CHMP INDICATED BENEFIT RISK ASSESSMENT NEGATIVE AS STUDY RESULTS BASED ON EVIDENCE FROM SINGLE PIVOTAL TRIAL, AMONG OTHER THINGS \n* PUMA BIOTECH -CHMP INDICATED BENEFIT RISK ASSESSMENT ALSO NEGATIVE AS 2- & 5-YEAR IDFS BENEFITS OBSERVED TO-DATE MAY LACK SUFFICIENT CLINICAL RELEVANCE Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-23T23:33:00.000+02:00", "crawled": "2018-01-23T23:47:35.000+02:00", "highlightTitle": ""}